Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanbin Zeng

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Journal of Neurology|May 28, 2025
Safety concerns of maternal antiseizure medications exposure on perinatal and offspring outcomes: a disproportionality analysis based on FDA adverse event reporting systemYanbin Zeng, Wanlong Lin, Wei Zhuang
Andrology|October 27, 2024
Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting systemYanbin Zeng, Wanlong Lin, Wei Zhuang
Journal of Clinical Pharmacology|April 12, 2023
Cardiovascular and Cerebrovascular Safety of Ranibizumab, Bevacizumab, and Aflibercept in Ocular Diseases: An Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) DatabaseYanbin Zeng, Xiaohui Guo, Fengjiao Xiao, et al.
Cancer Investigation|July 5, 2026
Profiling Immune-Related Adverse Events Associated with Imatinib: A Two-Decade Real-World Safety Study Based on FDA Adverse Event Reporting SystemYongfeng Zhu, Yanbin Zeng, Wanlong Lin, et al.
BMC Pharmacology & Toxicology|August 9, 2024
Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance studyWanlong Lin, Yanbin Zeng, Lizhu Weng, et al.
Micromachines|January 23, 2024
Design and Experiment Investigation on Soft Grippers with Modular Variable Stiffness StructurePengbing Zhao, Chuan Xiong, Zheng Gao, et al.
Expert Opinion on Drug Safety|April 18, 2023
PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS)Qiaoyun Wang, Fengjiao Xiao, Yanbin Zeng, et al.
Materials (Basel, Switzerland)|March 29, 2023
A Novel POP-Ni Catalyst Derived from PBTP for Ambient Fixation of CO<sub>2</sub> into Cyclic CarbonatesFen Wei, Jiaxiang Qiu, Yanbin Zeng, et al.
Expert Opinion on Drug Safety|October 8, 2024
Differences in safety profiles of anti-herpesvirus medications: a real-world pharmacovigilance study based on the FAERS databaseDan He, Dexuan Kong, Yanbin Zeng, et al.
BMC Infectious Diseases|May 9, 2024
Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting systemYunsong Li, Xiaoling Wang, Yufang Liao, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Journal of Neurology|May 28, 2025
Safety concerns of maternal antiseizure medications exposure on perinatal and offspring outcomes: a disproportionality analysis based on FDA adverse event reporting systemYanbin Zeng, Wanlong Lin, Wei Zhuang
Andrology|October 27, 2024
Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting systemYanbin Zeng, Wanlong Lin, Wei Zhuang
Journal of Clinical Pharmacology|April 12, 2023
Cardiovascular and Cerebrovascular Safety of Ranibizumab, Bevacizumab, and Aflibercept in Ocular Diseases: An Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) DatabaseYanbin Zeng, Xiaohui Guo, Fengjiao Xiao, et al.
Cancer Investigation|July 5, 2026
Profiling Immune-Related Adverse Events Associated with Imatinib: A Two-Decade Real-World Safety Study Based on FDA Adverse Event Reporting SystemYongfeng Zhu, Yanbin Zeng, Wanlong Lin, et al.
BMC Pharmacology & Toxicology|August 9, 2024
Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance studyWanlong Lin, Yanbin Zeng, Lizhu Weng, et al.
Micromachines|January 23, 2024
Design and Experiment Investigation on Soft Grippers with Modular Variable Stiffness StructurePengbing Zhao, Chuan Xiong, Zheng Gao, et al.
Expert Opinion on Drug Safety|April 18, 2023
PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS)Qiaoyun Wang, Fengjiao Xiao, Yanbin Zeng, et al.
Materials (Basel, Switzerland)|March 29, 2023
A Novel POP-Ni Catalyst Derived from PBTP for Ambient Fixation of CO<sub>2</sub> into Cyclic CarbonatesFen Wei, Jiaxiang Qiu, Yanbin Zeng, et al.
Expert Opinion on Drug Safety|October 8, 2024
Differences in safety profiles of anti-herpesvirus medications: a real-world pharmacovigilance study based on the FAERS databaseDan He, Dexuan Kong, Yanbin Zeng, et al.
BMC Infectious Diseases|May 9, 2024
Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting systemYunsong Li, Xiaoling Wang, Yufang Liao, et al.
Pageof 2